

### Trimurthi Drugs & Pharmaceuticals Ltd.

Date: 28-01-2012.

The Secretary, The Bombay Stock Exchange Limited Floor 25, P.J. Towers, Dalal Street, Mumbai. - 400 001

Sub: Outcome of the Board meeting.

W. OOPM The meeting of the Board of Directors of the company was held at 11:30 am today. The outcome of the meeting as under:

- 1.) Considered and approved the minutes of the previous board meeting.
- 2.) Considered and approved the un-audited Financials for the Quarter/half year ended 31st December, 2017. MARIE
- 3.) The Company has entered into a Manufacturing Agreement with M/s BHARAT PARENTERALS LIMITED, Vadodara, Gujrat for exclusive manufacture of Company's 12
- 4.) In addition, an exclusive Distribution Agreement is also being entered with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you

Yours truly,

For TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.

ARVIND KUMAR BHANGADIA

Managing Director



# Trimurthi Drugs & Pharmaceuticals Ltd.

### TRIMURTHI DRUGS AND PHARMACEUTICALS LIMITED

QUARTERLY RESULTS FOR THE QUARTER ENDED ON 31-12-2011

/De le Lakhe

_		Quarter ended			Nine Months ended		(Rs. In Lakhs Year ended
	Particulars			30/09/2010			31/03/2011
	7 313331313	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Net Sales / Income from Operations	442.68	522.65	133.29	895.52	1312.07	1651.9
2.	Other Income	23.89	15.10	19.10	58.13	39.86	62.0
3.	Total Income	466.57	537.75	152.39	953.65	1351.93	1714.0
4.	Expenditure						
	(Increase)/Decrease in stock in trade and work in Progress	11.74	(9.94)	15.91	33.94	(9.57)	(19.9
	b. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	1
	c. Purchase of Traded Goods	410.23	507.77	97.08	801.08	1246.38	1568.8
	d. Employees Cost	6.56	4.85	7.23	19,32	17.71	28.8
	e. Rent	1.68	1.71	1.77	5.13	5.13	0.0
	f. Depreciation	8.12	7.11	12.05	20,17	20.41	26.1
	g. Other Expenditure	6.00	7.57	2.81	16.99	26.61	39.3
	Total	444.33	519.07	136.85	896.63	1306.67	1643.1
5.	Interest	0.19	0.33	0.50	0.69	1.03	1.3
ò.	Exceptional items	Nil	Nil	Nil	Nil	Nil	1
7.	Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	22.05	18.68	15.04	56.33	44.23	69.5
3.	Tax Expense (Including Deferred and Finge Benefit tax)	5.30	NII	Nil	15.15	Nil	22.3
).	Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	16.75	18.68	15.04	41.18	44.23	47.2
0.	Extraorindary Items	Nil	Nil	Nil	Nil	Nil	
	Net Profit/ (Loss) for the period (9-10)	16.75	18.68	15.04	41.18	44.23	47.2
	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.00	675,00	675.00			
	Reserves excluding revaluation reserves as per	073.00	075,00	675.00	675.00	675.00	675.0
2	balance sheet of previous accounting year	111.15	97.47	444.45	*****	07.47	
	Earnings Per Share (EPS) #	111.15	87.47	111.15	111.15	87.47	111.1
	Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.25	0.28	0.22	0.61	0.66	0.7
5.	Public Share Holding						
	- Number of Shares	2016200	2016200	2016200	2016200	2016200	201620
	- Percentage of shareholding	29.87%	29.87%	29.87%	29.87%	29.87%	29.87
6.	Promoters and promoter group shareholding						
_	a. Pledged / encumbured	***	100				
_	- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	N
	- Percentage of Shares (of the shareholding of	2792	5000.0	92025	-		
	promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	N
	<ul> <li>Percentage of Shares (of the total share capital of the company)</li> </ul>	Nil	Nil	Nil	Nil	Nil	N
_	a. Non encumbured		13.7		.,	1311	
	- No of Equity Shares	4733800	4733800	4733800	4733800	4733800	4733800
	Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	
	- Percentage of Shares (of the total share capital of the company)	70.13%	70.13%	70.13%	70.13%	70.13%	70,13



## Trimurthi Drugs & Pharmaceuticals Ltd.

Segment Reporting

	Particulars	Quarter ended			Nine Months ended		(Rs. In Lakhs Year ended
randculars		31/12/2011	31/12/2010	30/09/2010	31/12/2011	31/12/2010	31/03/2011
1.	Segment Revenue	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	a. Pharma Business						riaditod
_	b. Financial Services	443.77	522,65	135.84	900.54	1312.07	1661.83
_		15.95	15.10	16.55	46.26	39.81	
_	c. Investments	8.20	0.00	0.00	58.74	THE RESERVE TO SERVE THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED	52.14
-	d. Trading in Shares	0.00	0.00	0.00	The state of the s	0.05	0.05
Tot		467.92	537.75	152.39	0.00	0.00	0.00
2.	Segment Profits			102.33	1005.54	1351.93	1714.02
	a. Pharma Business	1.23	4.60	0.00			
	b. Financial Services	The second secon	4.60	0.08	8.44	10.44	25.37
	c. Investment in shares	13.97	13.75	14.96	41.04	33.74	44.08
	d. Trading in Shares	6.85	0.00	0.00	6.85	0.05	0.05
Total		0.00	0.00	0.00	0.00	0.00	0.00
3,	Capital Employed	22.05	18.35	15.04	56.33	44.23	69.50
	a. Pharma Business	205.00					
	b. Financial Services	285.83	273.20	273.44	285.83	273.20	321.06
	c. Investments	415.50	395.11	423.05	415.50	395.11	328.49
	d. Trading in Shares	50.54	50.54	51.89	50.54	50.54	51.89
otal		Nil	Nil	0.00	Nil	Nil	0.00
		751.87	718.85	748.38	751.87	718.85	701.44

#### Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 28-01-2012.
- 2. The finanical results for the quarter ended 31-12-2011 have been reviewed by the statutory auditors in pursuance of listing agreement.
- 3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- 4. The status of investor greviences for the quarter ended 31-12-2011
  - a. pending at the beginning Nil
  - b. received 2
  - c. settled 2
  - d. pending at the end Nil

Place: Hyderabad Date : 28-01-2012. for: TRIMURTHI DRUGS AND PHARMACEUTICALS LIMITED

Arvind Humar Bhangadia Managing Director